ES2493316T3 - GLYX-13 para uso en un método para tratar depresión que no responde al tratamiento - Google Patents

GLYX-13 para uso en un método para tratar depresión que no responde al tratamiento Download PDF

Info

Publication number
ES2493316T3
ES2493316T3 ES10822514.5T ES10822514T ES2493316T3 ES 2493316 T3 ES2493316 T3 ES 2493316T3 ES 10822514 T ES10822514 T ES 10822514T ES 2493316 T3 ES2493316 T3 ES 2493316T3
Authority
ES
Spain
Prior art keywords
glyx
treatment
respond
treat depression
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10822514.5T
Other languages
English (en)
Inventor
Joseph Moskal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University filed Critical Northwestern University
Application granted granted Critical
Publication of ES2493316T3 publication Critical patent/ES2493316T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Glass Compositions (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Ceramic Products (AREA)

Abstract

GLYX-13 para uso en un método para tratar depresión que no responde al tratamiento en un paciente resistente al tratamiento que lo necesita, en el que GLYX-13 debe administrarse a dicho paciente, mediante lo cual se alivia sustancialmente al menos un síntoma en dicho paciente en el plazo de aproximadamente 14 días.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11

Claims (1)

  1. imagen1
ES10822514.5T 2009-10-05 2010-10-05 GLYX-13 para uso en un método para tratar depresión que no responde al tratamiento Active ES2493316T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US248650P 2000-11-16
US24865009P 2009-10-05 2009-10-05
PCT/US2010/051415 WO2011044089A2 (en) 2009-10-05 2010-10-05 Methods of treating depression and other related diseases

Publications (1)

Publication Number Publication Date
ES2493316T3 true ES2493316T3 (es) 2014-09-11

Family

ID=43857351

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10822514.5T Active ES2493316T3 (es) 2009-10-05 2010-10-05 GLYX-13 para uso en un método para tratar depresión que no responde al tratamiento
ES15171991T Active ES2721448T3 (es) 2009-10-05 2010-10-05 GLYX-13 para uso en el tratamiento de enfermedad de Alzheimer, enfermedad de Parkinson y enfermedad de Huntington

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15171991T Active ES2721448T3 (es) 2009-10-05 2010-10-05 GLYX-13 para uso en el tratamiento de enfermedad de Alzheimer, enfermedad de Parkinson y enfermedad de Huntington

Country Status (12)

Country Link
EP (4) EP2485751B1 (es)
CY (1) CY1118530T1 (es)
DK (2) DK2985032T3 (es)
ES (2) ES2493316T3 (es)
HR (1) HRP20140784T1 (es)
HU (1) HUE043807T2 (es)
PL (2) PL2985032T3 (es)
PT (2) PT2985032T (es)
RS (1) RS53513B1 (es)
SI (1) SI2485751T1 (es)
SM (1) SMT201400117B (es)
WO (1) WO2011044089A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2331571B1 (en) 2008-09-18 2015-08-26 Northwestern University Nmda receptor modulators and uses thereof
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
SG10201811584RA (en) 2010-02-11 2019-01-30 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
SG10202010665YA (en) * 2011-04-27 2020-11-27 Univ Northwestern Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
WO2014059326A2 (en) * 2012-10-12 2014-04-17 Northwestern University Methods of identifying compounds for treating depression and other related diseases
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
AU2014212485C1 (en) 2013-01-29 2018-10-25 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
HUE043843T2 (hu) 2013-01-29 2019-09-30 Aptinyx Inc Spiro-laktám NMDA receptor modulátorok és azok alkalmazása
AU2014212501A1 (en) 2013-01-29 2015-07-30 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
EA201591404A1 (ru) 2013-01-29 2016-01-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
MX2016007716A (es) * 2013-12-13 2017-03-31 Univ Northwestern Metodos para el tratamiento de trastornos cerebrales o la identificacion de biomarcadores relacionados con estos.
CN105327349A (zh) * 2014-06-18 2016-02-17 上海翰森生物医药科技有限公司 Nmda受体拮抗剂的医药用途及其药物组合物
KR20170018072A (ko) * 2014-06-23 2017-02-15 노오쓰웨스턴 유니버시티 편두통을 치료 또는 경감시키는 방법
SG11201701134XA (en) * 2014-08-14 2017-03-30 Naurex Inc Methods of treating depression using nmda modulators
CA3002070A1 (en) * 2015-10-16 2017-04-20 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
WO2017189920A1 (en) * 2016-04-28 2017-11-02 The Trustees Of The University Of Pennsylvania Method of drug design and optimisation utilizing stereochemical mimicry
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3024606C (en) 2016-05-19 2019-09-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112019001768A2 (pt) 2016-08-01 2019-06-11 Aptinyx Inc moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
BR112019001926A2 (pt) 2016-08-01 2019-08-06 Aptinyx Inc moduladores do receptor nmda espiro-lactama e bis-espiro-lactama e usos destes
CA3031534C (en) 2016-08-01 2023-10-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP7032378B2 (ja) 2016-08-01 2022-03-08 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用
EP3490990B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda modulators and methods of using same
WO2019152687A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
US20030065138A1 (en) * 2001-03-07 2003-04-03 University Of Utah Research Foundation Linear gamma-carboxyglutamate rich conotoxins
WO2002072609A2 (en) * 2001-03-12 2002-09-19 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
WO2005014797A2 (en) * 2003-08-08 2005-02-17 The Burnham Institute P16 mediated regulation of nmda receptors
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders

Also Published As

Publication number Publication date
EP2485751B1 (en) 2014-05-21
SMT201400117B (it) 2014-11-10
EP2485751A4 (en) 2013-03-13
WO2011044089A3 (en) 2012-02-16
EP2485751A2 (en) 2012-08-15
EP2985032B1 (en) 2019-01-02
RS53513B1 (en) 2015-02-27
HUE043807T2 (hu) 2019-09-30
CY1118530T1 (el) 2017-07-12
DK2985032T3 (en) 2019-04-15
ES2721448T3 (es) 2019-07-31
PT2485751E (pt) 2014-09-01
HRP20140784T1 (hr) 2014-10-10
PL2985032T3 (pl) 2019-07-31
SI2485751T1 (sl) 2014-10-30
WO2011044089A2 (en) 2011-04-14
DK2485751T3 (da) 2014-08-18
EP2985032A1 (en) 2016-02-17
PT2985032T (pt) 2019-04-24
EP2813236A1 (en) 2014-12-17
EP3488856A1 (en) 2019-05-29
PL2485751T3 (pl) 2014-10-31

Similar Documents

Publication Publication Date Title
ES2493316T3 (es) GLYX-13 para uso en un método para tratar depresión que no responde al tratamiento
ES2613674T3 (es) Uso del organismo fúngico Pythium oligandrum
PH12015502275A1 (en) Therapuetic uses of empagliflozin
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
BR112015020466A2 (pt) inibidores de cdc7
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
AR059390A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
UY32030A (es) "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
ES2488407T3 (es) Preparación farmacéutica que contiene lipasa de origen bacteriano
CR10433A (es) Compuestos organicos y sus usos
EA201001771A1 (ru) Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
AR060880A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
ES2563777T3 (es) Compuestos de nitrona para tratar la pérdida auditiva sensorineural
PA8850801A1 (es) Compuestos útiles para inhibir chk1
CL2011001712A1 (es) Combinacion de 0,1 a 1 mg de al menos un estimulador de sgc seleccionado de un grupo definido con 2,5 a 20 mg de un inhibidor de pde5 seleccionado de otro grupo; formulacion farmaceutica que la comprende y uso en el tratamiento de la disfuncion sexual masculina.
MX2015012520A (es) Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con depresion.
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
AR086422A1 (es) Metodo para el tratamiento de tumores solidos avanzados, volasertib
ES2531516T3 (es) Uso de escina
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
ES2534911T3 (es) Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
MX2010012593A (es) Metodos para el tratamiento de lesion asociada con exposicion a especie alcalina.